ABO and Rh Blood Group Frequencies in Acute Leukemia Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2027-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia. By analyzing medical records from leukemia cases, the study seeks to identify any potential associations between blood group types and the occurrence of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relation of C-reactive Protein/ Albumin Ratio and Coagulation Profile in Acute Myeloid Leukemia Patients

NCT06714071

AML

NOT_YET_RECRUITING

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

NCT07036809

Acute Leukemia

RECRUITING

Immunophenotyping and Xist Gene in AML

NCT04288739

Acute Myeloid Leukemia

UNKNOWN

Frequency and Risk Factors of Acute Myeloid Leukemia

NCT05787951

Myeloid Leukemia

UNKNOWN

Outcomes of Acute Myeloid Leukemia Patients

NCT04392310

Acute Myeloid Leukemia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute leukemia is a group of hematologic malignancies characterized by the rapid proliferation of immature blood cells, leading to bone marrow failure and systemic complications. It is broadly classified into two main types: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), depending on the lineage of the malignant cells. Despite advancements in the understanding of leukemia pathogenesis, the etiology remains multifactorial and incompletely understood.

Recent studies have suggested a potential association between blood group antigens-particularly those of the ABO and Rh systems-and the risk of developing various types of cancer, including hematological malignancies. The ABO antigens are expressed not only on red blood cells but also on epithelial and endothelial cells, and may influence cancer biology through mechanisms involving immune response modulation, cell adhesion, and inflammation.

Several epidemiological investigations have explored the relationship between ABO and Rh blood groups and malignancies such as gastric, pancreatic, breast, and hematologic cancers. However, data regarding their association with acute leukemia are still limited, inconsistent, and often vary across different populations and study designs.

This study is a retrospective observational analysis conducted at the Clinical Pathology Department, South Egypt Cancer Institute, Assiut University. It aims to assess the frequencies of ABO and Rh blood groups among patients diagnosed with acute leukemia over a defined period. The findings will be compared to blood group distributions in healthy blood donors to explore any statistically significant associations.

Understanding whether certain blood group antigens are associated with an increased or decreased risk of acute leukemia may help identify at-risk individuals, contribute to risk stratification, and provide further insight into the biology of leukemogenesis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with de-novo acute leukemia (ALL or AML)
* Diagnosis confirmed between 2022 and 2025
* ABO and Rh blood group data available
* Patients treated at or referred to South Egypt Cancer Institute, Assiut University

Exclusion Criteria

* Incomplete or missing blood group data
* Presence of other malignancies or chronic systemic illnesses
* History of blood transfusion prior to diagnosis or blood grouping

Eligible Sex

ALL

Accepts Healthy Volunteers

No